OCT 25, 2016 12:34 PM PDT

New Compound in Onions Halts Ovarian Cancer Proliferation

WRITTEN BY: Xuan Pham
A study from the University of Japan finds that certain compounds in onions have anticancer effects against ovarian cancer. Onion lovers rejoice!
 
Known for its polarizing taste and pungent smell, onions are high in many vitamins and antioxidants. Studies have linked onions to health benefits, like strengthening the immune system, lowering blood pressure, and even fighting cancer.
 

One compound, aptly called onionin A (ONA), was recently identified by researchers at the Kumamoto University in Japan. ONA is high in sulfur and researchers believed it can squelch a tumor microenvironment. In particular, the team was especially interested in how ONA may act on epithelia ovarian cancer (EOC), which is often associated with tumor-associated macrophages.
 
In pre-clinical trials, the researchers treated EOC cells with the onion-derived compound. They found that ONA directly suppressed cancer cell proliferation. Furthermore, the effect appeared synergistic when combined with other anticancer drugs.
 
When the compound was used to treat a mouse model of EOC, the team found increased survival time. Molecular research also revealed that the signals for chemo-resistance was abolished with the application of ONA, suggesting a mechanism for how ONA acts on cancer cells.
 
The team concluded that “ONA is considered useful for the additional treatment of patients with ovarian cancer owing to its suppression of the pro-tumor activation of [tumor-associated macrophages] and direct cytotoxicity against cancer cells."
 

Of note, this first study to investigate the effect of an onion compound in ovarian cancer did not find any side effects in the animals. This, combined with the promising positive anticancer effects, could mean a faster path to human clinical trials and treatment.
 
Ovarian cancers have one of the highest mortality rates, ranking fifth in cancer deaths among women. Of the 22,000 new estimated cases of ovarian cancer this year, only 10-15 percent of patients will be successfully treated. Unfortunately, in the large percent of remaining patients, the cancer doesn’t respond to treatment, or will inevitably return with a vengeance. As such, research into low risk, natural compounds like ONA may be fruitful to fight this deadly disease.

Additional sources: MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 13, 2018
Cancer
SEP 13, 2018
Breast tumors can stop their own metastasis
According to the American cancer society, metastatic breast cancers or stage 4 breast cancers have 5-years survival rate of 22% which is lower than at early stages. Metastatic breast cancer...
SEP 26, 2018
Videos
SEP 26, 2018
Cancer Immunotherapy
Video illustration about how tumor cells are sensed and destroyed by the immune system and how tumors evolve and detect immune-mediated eliminations, as well as iimmunotherapies associated....
OCT 08, 2018
Immunology
OCT 08, 2018
Natural Killer Cells to Aid in Cancer Therapy
Researchers utilize nanoparticles to stimulate NK cells that induce tumor cells to express PDL1, a protein involved in immune response messaging...
OCT 31, 2018
Cancer
OCT 31, 2018
Researchers identify a protein marker that induces dormancy in metastatic breast cancer
Researchers at the Mount Sinai hospital identified for the first time a protein marker that could indicate whether breast cancer will further metastasize or remains in a dormant state accordi...
DEC 05, 2018
Immunology
DEC 05, 2018
Combo-Kick to Battle Lymphoma
Combination immunotherapy has provided remission for patients suffering from Hodgkin's Lymphoma...
JAN 23, 2019
Immunology
JAN 23, 2019
Unleashing the Immune System on Cancer
A team of international researchers has discovered that there may me a more from the immune system to aid in the battle against cancer...
Loading Comments...